Summary
This video features Dr. Rick Doblin, founder of MAPS, discussing the evolving landscape of psychedelic research and therapy. He highlights the recent shift towards bipartisan support, including a White House executive order and federal funding, emphasizing the potential of psychedelics like MDMA and psilocybin to treat conditions like PTSD and depression by tapping into neuroplasticity. Doblin also addresses the challenges of for-profit vs. altruistic models, the historical context of psychedelic use, the complexities of drugs like ibogaine, and the crucial role of therapy and integration for sustainable healing. The discussion also touches upon the rise of psychedelic churches and the future of wider accessibility.
Key Insights
Republicans have emerged as champions of psychedelic research, a significant political shift from past decades.
Dr. Doblin notes that for the first time, Republicans are actively supporting psychedelic research, a stark contrast to the Nixon era's crackdown. This shift is attributed to strategies focusing on bipartisan support, particularly through initiatives involving veterans. An executive order from President Trump, the signing ceremony of which was attended by Joe Rogan, signaled this new political alignment, even involving discussions about the historical reasons for psychedelic criminalization.
The pharmaceutical industry's focus on symptom management with SSRIs contrasts with psychedelics' potential to address root causes via neuroplasticity.
Doblin highlights that current psychiatric drugs, like SSRIs, often focus on managing symptoms rather than addressing the underlying issues of mental illness. He contrasts this with psychedelics, which can tap into the brain's neuroplasticity, enabling deeper healing. The overreliance on daily medications for extended periods is questioned, with a growing recognition of the limitations of this approach, especially for treatment-resistant cases. The movement towards cross-training therapists in various psychedelics to customize treatments is presented as a more holistic alternative.
Ibogaine offers unique potential for opioid withdrawal but carries significant cardiac risks requiring careful medical supervision.
Ibogaine is discussed for its remarkable ability to help individuals overcome opioid withdrawal and reset the brain, potentially reducing addiction. However, its use is associated with 'QT prolongation,' a cardiac risk that can be dangerous. While clinics have operated without fatalities under medical supervision, the FDA has places a clinical hold on ibogaine studies due to this risk. Doblin argues that a rational risk-benefit analysis, considering the potential fatality of untreated opioid dependence, suggests ibogaine can be safely administered under medical supervision, and challenges the FDA's stringent cutoff points.
The rise of 'psychedelic churches' represents an emerging, often open, avenue for accessing psychedelic substances, leveraging religious freedom arguments.
Doblin describes the proliferation of hundreds of 'psychedelic churches' across the US. These organizations, some with indigenous roots and others modern, use religious freedom arguments to operate openly, often distributing psychedelics like psilocybin as 'offerings' or providing a spiritual framework for their use. Examples like the Church of Ambrosia in Oakland, which functions as a de facto dispensary for mushrooms, highlight this trend. This development is seen as another way to increase access to psychedelics, distinct from but sometimes overlapping with medical or therapeutic pathways.
Sections
The Historical Context and Current State of Psychedelic Research
The 1970 Controlled Substances Act and Nixon's War on Drugs halted psychedelic research for decades.
Following the 1960s' burgeoning psychedelic research, the Controlled Substances Act of 1970 and President Nixon's subsequent War on Drugs led to a global halt in psychedelic studies for many years. This represented a significant setback for scientific exploration of these compounds.
A shift at the FDA in the 1990s, influenced by the AIDS movement, reopened doors for psychedelic research.
Beginning in 1992, a new group of reviewers at the FDA, partly inspired by the ACT UP movement's activism regarding AIDS treatments, created the 'pilot drug evaluation staff.' This group began to explore new ways to evaluate drugs more quickly and opened the door for research into the beneficial uses of psychedelics.
Nonprofits have raised significant funds, but the pharmaceutical industry has invested billions, driving current research.
While non-profits like MAPS have raised approximately $300 million in donations to advance psychedelic research, the pharmaceutical industry has since invested close to $6 billion. This massive influx of capital from the pharma sector is fueling the current surge in psychedelic research globally.
Spravato, a form of ketamine, is approved without therapy, serving as a profitable but less durable model.
Spravato, an isomer of ketamine approved by Johnson & Johnson, serves as the sole entry in the bullseye of FDA approval. Its approval without accompanying therapy makes it a profitable model for shareholders, as results are less durable, necessitating repeat purchases. This contrasts with therapies that, when paired with psychedelics, yield more lasting benefits but are less lucrative for pharmaceutical companies.
Several psychedelics are in late-stage FDA trials for various mental health conditions.
In the inner ring of Phase III studies, several psychedelic compounds are progressing. These include psilocybin for major depressive disorder (USA) and treatment-resistant depression (Compass Pathways), LSD for generalized anxiety disorder, and 5-MeO-DMT for depression. Many of these are nearing completion or are in the FDA's review process.
Political and Historical Dimensions of Psychedelics
Psychedelics were historically associated with counterculture, leading to their criminalization as a political tool.
Psychedelics were deeply intertwined with counterculture movements in the 1960s, associated with anti-war, environmental, and civil rights activism. This alignment, especially the idea of expanded consciousness, was seen as progressive or liberal. In contrast, President Nixon's administration viewed these movements and the associated drug use as threats to the conservative order. John Ehrlichman later confirmed that the drug war was used to disrupt meetings and criminalize activists associated with these movements, with an awareness that drug risks were exaggerated.
Ancient Western culture, including the Eleusinian Mysteries, incorporated psychoactive substances.
The foundation of Western culture, including the Greek tradition, featured practices like the Eleusinian Mysteries (396 AD). Participants drank a potion called 'Kykeon,' speculated to contain LSD-like compounds from ergot fungus, to explore spiritual and existential questions. Notably, women and slaves could participate, indicating a broad societal engagement despite later suppression.
Religious and historical powers often suppressed direct spiritual experiences facilitated by psychedelics.
Throughout history, from the Catholic Church's suppression of pagan rituals to the Spanish conquistadors viewing peyote as devil worship, established power structures have often sought to eliminate direct spiritual connections facilitated by psychedelics. Shamans and individuals working with non-ordinary states of consciousness were frequently targeted and persecuted.
The opioid crisis, exacerbated by pharmaceutical companies and FDA oversight, is linked to the same regulatory environments that affected psychedelics.
The same 'pilot drug evaluation staff' at the FDA that helped open doors to psychedelics also facilitated the entry of OxyContin. A former FDA official involved with this process later moved to Purdue Pharma, highlighting a potential conflict of interest and a 'collusion' between the pharmaceutical industry, FDA, and a focus on shareholder profits over patient well-being. This led to the devastating opioid epidemic due to overprescription and inadequate oversight.
Veterans with PTSD became a key demographic for building bipartisan support for psychedelic research.
Recognizing the significant suffering and high cost associated with PTSD among veterans, MAPS focused on this population to build bipartisan support for psychedelic therapies. The high rates of PTSD in Vietnam, Iraq, and Afghanistan veterans, and the immense financial burden on the VA, made them a sympathetic patient group. This strategy was instrumental in gaining political traction for psychedelic research.
The Role of Therapy and Integration in Psychedelic Use
Psychedelic experiences can bring up deep psychological material, necessitating therapeutic integration.
Dr. Doblin emphasizes that psychedelic medicines tap into 'deepest wounds, deepest loves, formative memories, and ancestral memories.' These experiences are not predictable like conventional medication, making integration with therapy crucial. Without integration, the potential for lasting change is diminished.
Ibogaine's effectiveness in opioid withdrawal is linked to 'resetting' the brain, but this also poses overdose risks if relapse occurs.
Ibogaine's unique ability to help users through opioid withdrawal is significant. It can reset the brain's dependency in a short period. However, this 'reset' can be dangerous if an individual relapses and uses their previous dosage, as their tolerance will have decreased, increasing the risk of fatal overdose. Responsible medical supervision is therefore critical.
Intergenerational trauma can be scientifically understood and potentially altered through successful therapy.
Research by figures like Rachel Yehuda suggests epigenetic mechanisms by which stress and anxiety are passed from parents to children. Preliminary evidence indicates that successful therapy, including MDMA-assisted therapy, may alter these epigenetic markers, offering a scientific basis for addressing inherited psychological burdens.
MAPS' Public Benefit Corporation model prioritizes patient well-being over maximizing shareholder profits.
MAPS created a for-profit Public Benefit Corporation to navigate the commercialization of MDMA. Unlike traditional corporations, its mission is to prioritize public benefit (patient well-being) over maximizing profits, offering a potential counter-model to the purely capitalist approach often seen in the pharmaceutical industry.
The therapeutic alliance—the connection between therapist and patient—is the most critical factor in psychotherapy outcomes.
Research in psychotherapy outcome indicates that the therapeutic alliance, characterized by safety, non-judgment, and connection, is paramount to successful treatment. This alliance can be fostered not only by therapists but also through peer support, highlighting the importance of relationships in healing.
The core of therapeutic psychedelic use is integration, not just the experience itself.
Unlike recreational use, which focuses on the immediate experience, therapeutic psychedelic use emphasizes integration—applying the insights gained during the psychedelic state to one's life. This involves reflecting on dreams, processing emotions, and making lasting changes to behavior and perspective. Skipping this process significantly limits the long-term benefits.
Neuroplasticity, enhanced by psychedelics, allows the brain to rewire and overcome trauma.
Psychedelics can induce a state of neuroplasticity, where the brain becomes more amenable to change. This allows individuals to process and reframe traumatic memories, altering neural pathways and overcoming deeply ingrained negative patterns. The extended neuroplastic state induced by some psychedelics, like ibogaine, provides a critical window for this non-drug work.
Challenges and Future Directions in Psychedelic Medicine
For-profit companies risk sidelining therapy in favor of drug sales, mirroring Spravato's model.
A major concern is that for-profit psychedelic companies may de-emphasize or eliminate therapy to maximize profits. They may follow the model of Spravato (ketamine), which achieves high sales through continuous use without therapy. This approach fails to leverage neuroplasticity and perpetuates a cycle of dependence on the drug, prioritizing shareholder returns over patient healing.
The executive order aims to expedite FDA reviews and includes a 'Right to Try' provision for psychedelics.
The recent White House executive order prioritizes three companies (Compass Pathways, Eonian, and Transcend) for faster FDA reviews and allocates $50 million for psychedelic research, possibly for ibogaine. It also extends the 'Right to Try' legislation to schedule one drugs, allowing individuals with treatment-resistant conditions to access investigational drugs outside of clinical trials, though DEA and company policies may still pose barriers.
Transparency in data sharing is crucial to build trust and ensure approvals are science-based, not political.
To counter concerns that psychedelic approvals might be politically motivated rather than science-driven, Dr. Doblin stresses the importance of transparency. Pharma companies should make their data and communications with the FDA publicly accessible, similar to MAPS' approach, to build confidence and validate the scientific basis for these treatments.
Psychedelic-assisted couples therapy, even for couples without diagnosed conditions, is being explored.
MAPS is initiating studies on MDMA-assisted couples therapy, aiming to address relationship dynamics and pre-conceived generational trauma before conception. This research challenges the FDA's traditional focus on disease by exploring applications for personal growth and relationship improvement, requiring novel outcome measures beyond simple relationship continuation.
The opioid crisis, fueled by pharmaceutical practices, is now funding research into potential psychedelic cures.
The massive financial settlements paid by pharmaceutical companies like Purdue Pharma due to the opioid crisis have provided billions of dollars to states. This money is now being redirected towards research, including exploring ibogaine as a treatment for opioid dependence. This represents a significant, albeit tragic, shift in funding for psychedelic research.
Globalizing access to psychedelics requires training local healers and adapting treatments for diverse cultural contexts.
As MAPS expands its work globally, there's a recognition that local healers, not just Western therapists, will be crucial. Training will be needed for individuals in roles like midwives, nurses, and social workers. Treatments may also shift towards group settings, adapting to cultural norms and resource availability, aiming for durable outcomes rather than just drug sales.
The development of a 'Gross National Trauma Measure' is proposed to track progress in reducing collective suffering.
Inspired by Bhutan's Gross National Happiness index, Dr. Doblin suggests creating a 'Gross National Trauma Measure.' This metric would aim to quantify and track the reduction of individual and multigenerational trauma through increased access to psychedelics and other treatments, providing a benchmark for societal progress in healing.
Psychedelic churches and state-level reforms offer alternative access pathways outside traditional medical models.
Beyond medical approvals, psychedelic churches and state-level initiatives (like in Oregon and Colorado) provide alternative access. These models, often less regulated and accessible without a diagnosis, represent a significant expansion of availability, though they may not be covered by insurance and require careful consideration of training and oversight.
Personal Reflections and Philosophical Considerations
Dr. Doblin's personal ibogaine and LSD experience involved intense psychological struggle and a profound realization about self-criticism.
In 1985, Dr. Doblin underwent a combined ibogaine and LSD experience intended to prepare him for advocating for psychedelics. The prolonged physical discomfort and psychological struggle led to a breakthrough where he realized his self-criticism was linked to self-hatred and a fear of death. He learned to reframe self-criticism as a tool for quality and learning, rather than a source of shame, leading to a sense of peace and acceptance.
William James's caution against accepting psychedelic revelations without critical reflection is paramount.
Drawing on the philosophy of William James, Dr. Doblin emphasizes that insights gained during psychedelic states, even those feeling deeply profound or divinely inspired, must be critically examined and integrated. The potential for grandiosity or misinterpretation requires careful reflection and a solid integration process to discern true spiritual life from mere experience.
The concept of neuroplasticity implies the brain's capacity for change, even in response to trauma.
Neuroplasticity is central to the transformative potential of psychedelics. It means the brain is not fixed, but can rewire itself, particularly after trauma. This allows for the reprocessing of painful memories and the development of new, healthier perspectives and emotional responses, offering a path beyond conditions like PTSD, which were once thought to be permanent.
MDMA's pro-social effects are evolutionarily conserved, suggesting a fundamental biological basis for connection.
Experiments with MDMA on octopuses demonstrated that the drug enhanced pro-social behavior, even in these solitary creatures. This finding suggests that MDMA's capacity to foster connection and reduce fear is evolutionarily conserved and predates verbal language, indicating a deep biological mechanism for social bonding that psychedelics can activate.
Treating trauma at an earlier age, with appropriate support, could be more beneficial than delaying treatment.
While concerns exist about administering psychedelics to developing brains, Dr. Doblin argues that for traumatized children, whose brains may not be developing normally, early intervention with supportive 'psychedelic-assisted therapy' could be more beneficial. He contrasts this with the age limits imposed by drug warriors and highlights ancestral cultural practices that don't restrict age for spiritual experiences.
The 'full expression of an emotion' leads to its resolution, a concept Stanislav Grof described as its 'funeral pyre'.
Stanislav Grof's concept suggests that truly experiencing and completing an emotion, even intensely painful ones like despair or terror, leads to its resolution. Resisting or fighting these emotions prolongs suffering, while allowing for their full expression, as facilitated by psychedelics, can be transformative. This is crucial for integrating difficult experiences and moving towards healing.
Founding a public benefit corporation is a strategy to balance capitalism with altruism in psychedelic drug development.
MAPS' creation of a public benefit corporation was a deliberate effort to navigate the pharmaceutical landscape. This structure allows for profit while prioritizing patient well-being over maximizing shareholder returns, addressing the inherent tension between commercial interests and the therapeutic goals of psychedelic medicine.
Finding common ground across political divides is essential for progress, especially in polarized times.
Dr. Doblin shares an anecdote about receiving funding from Rebecca Mercer, a figure associated with conservative politics, for veteran research. Supreme Court Justice Stephen Breyer's advice—that democracy requires finding common ground with those with whom you disagree—underscores the importance of this approach, which has been key to building bipartisan support for psychedelic issues.
Ask a Question
*Uses 1 Wisdom coin from your coin balance